IBB Quote, Financials, Valuation and Earnings

First Trust Health Care AlphaDEX Fund has a net margin of -- compared to iShares Biotechnology ETF's net margin of --. iShares Biotechnology ETF's return on equity of -- beat First Trust Health Care AlphaDEX Fund's return on equity of --.

iShares Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Health Care AlphaDEX Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Biotechnology ETF has higher upside potential than First Trust Health Care AlphaDEX Fund, analysts believe iShares Biotechnology ETF is more attractive than First Trust Health Care AlphaDEX Fund.

iShares Biotechnology ETF has a beta of 0.740, which suggesting that the stock is 26.046% less volatile than S&P 500. In comparison First Trust Health Care AlphaDEX Fund has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.906%.

iShares Biotechnology ETF has a quarterly dividend of $0.06 per share corresponding to a yield of 0.29%. First Trust Health Care AlphaDEX Fund offers a yield of 0.41% to investors and pays a quarterly dividend of $0.09 per share. iShares Biotechnology ETF pays -- of its earnings as a dividend. First Trust Health Care AlphaDEX Fund pays out -- of its earnings as a dividend.

iShares Biotechnology ETF quarterly revenues are --, which are smaller than First Trust Health Care AlphaDEX Fund quarterly revenues of --. iShares Biotechnology ETF's net income of -- is lower than First Trust Health Care AlphaDEX Fund's net income of --. Notably, iShares Biotechnology ETF's price-to-earnings ratio is -- while First Trust Health Care AlphaDEX Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Biotechnology ETF is -- versus -- for First Trust Health Care AlphaDEX Fund. Usually stocks with elevated PS ratios are considered overvalued.

Invesco Nasdaq Biotechnology ETF has a net margin of -- compared to iShares Biotechnology ETF's net margin of --. iShares Biotechnology ETF's return on equity of -- beat Invesco Nasdaq Biotechnology ETF's return on equity of --.

iShares Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Nasdaq Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Biotechnology ETF has higher upside potential than Invesco Nasdaq Biotechnology ETF, analysts believe iShares Biotechnology ETF is more attractive than Invesco Nasdaq Biotechnology ETF.

iShares Biotechnology ETF has a beta of 0.740, which suggesting that the stock is 26.046% less volatile than S&P 500. In comparison Invesco Nasdaq Biotechnology ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

iShares Biotechnology ETF has a quarterly dividend of $0.06 per share corresponding to a yield of 0.29%. Invesco Nasdaq Biotechnology ETF offers a yield of 1.13% to investors and pays a quarterly dividend of $0.06 per share. iShares Biotechnology ETF pays -- of its earnings as a dividend. Invesco Nasdaq Biotechnology ETF pays out -- of its earnings as a dividend.

iShares Biotechnology ETF quarterly revenues are --, which are smaller than Invesco Nasdaq Biotechnology ETF quarterly revenues of --. iShares Biotechnology ETF's net income of -- is lower than Invesco Nasdaq Biotechnology ETF's net income of --. Notably, iShares Biotechnology ETF's price-to-earnings ratio is -- while Invesco Nasdaq Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Biotechnology ETF is -- versus -- for Invesco Nasdaq Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.

iShares US Medical Devices ETF has a net margin of -- compared to iShares Biotechnology ETF's net margin of --. iShares Biotechnology ETF's return on equity of -- beat iShares US Medical Devices ETF's return on equity of --.

iShares Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares US Medical Devices ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Biotechnology ETF has higher upside potential than iShares US Medical Devices ETF, analysts believe iShares Biotechnology ETF is more attractive than iShares US Medical Devices ETF.

iShares Biotechnology ETF has a beta of 0.740, which suggesting that the stock is 26.046% less volatile than S&P 500. In comparison iShares US Medical Devices ETF has a beta of 0.904, suggesting its less volatile than the S&P 500 by 9.601%.

iShares Biotechnology ETF has a quarterly dividend of $0.06 per share corresponding to a yield of 0.29%. iShares US Medical Devices ETF offers a yield of 0.46% to investors and pays a quarterly dividend of $0.11 per share. iShares Biotechnology ETF pays -- of its earnings as a dividend. iShares US Medical Devices ETF pays out -- of its earnings as a dividend.

iShares Biotechnology ETF quarterly revenues are --, which are smaller than iShares US Medical Devices ETF quarterly revenues of --. iShares Biotechnology ETF's net income of -- is lower than iShares US Medical Devices ETF's net income of --. Notably, iShares Biotechnology ETF's price-to-earnings ratio is -- while iShares US Medical Devices ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Biotechnology ETF is -- versus -- for iShares US Medical Devices ETF. Usually stocks with elevated PS ratios are considered overvalued.